neoadjuvant therapy with trametinib and dabrafenib in high risk resectable braf-mutant melanoma
Published 7 years ago • 299 plays • Length 2:31Download video MP4
Download video MP3
Similar videos
-
2:40
neoadjuvant targeted therapy in braf v600 mutated melanoma
-
0:59
the success of the dabrafenib and trametinib combination in braf-mutated melanoma
-
0:56
5-year follow-up: dabrafenib plus trametinib reduces relapse risk in melanoma
-
2:56
treating braf v600e-mutant nsclc with dabrafenib and trametinib
-
2:51
combi-ad: long-term follow-up of dabrafenib and trametinib in braf-mutated melanoma
-
4:08
updates from combi-ad: dabrafenib and trametinib for melanoma
-
0:53
dabrafenib plus trametinib demonstrates benefit in braf-mutant melanoma
-
3:05
dabrafenib and trametinib: a promising combination for the treatment of melanoma
-
2:16
dr. rodabe n. amaria on dabrafenib plus trametinib in melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
27:18
adjuvant and neoadjuvant dilemmas
-
2:29
braf mutated melanoma: targeted or immunotherapy?
-
1:31
dr. daud on dabrafenib/trametinib vs immunotherapy in melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
2:46
long-term outcomes with dabrafenib plus trametinib in braf v600-mutant melanoma
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
1:11
dr. weber on the fda approval of adjuvant dabrafenib/trametinib in braf-mutant melanoma
-
6:28
dabrafenib and trametinib in braf-mutated nsclc